Table 3.
Changes in Finger-to-Floor Distance During Treatment (ITT Population)
| Treatment Group/Study Visits | Mean FFD (SD) | Mean Differencea (95%CI) |
P-valueb |
|---|---|---|---|
| Group A (n=289) | |||
| Pretreatment | 28.1 (7.4) | ||
| Visit 2 | 17.4 (8.0) | 10.7 (9.8, 11.7) | <0.0001 |
| Visit 3 | 13.5 (7.7) | 14.6 (13.5, 15.8) | <0.0001 |
| Group B (n=269) | |||
| Pretreatment | 27.3 (7.5) | ||
| Visit 2 | 14.5 (8.2) | 12.8 (11.7, 13.9) | <0.0001 |
| Visit 3 | 9.6 (6.2) | 17.7 (16.6, 18.9) | <0.0001 |
Notes: Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamins B1, B6, and B12. aFrom pretreatment; bTukey’s multiple comparisons test.
Abbreviation: FFD, finger-to-floor distance (cm).